Lung Cancer
Volume 68, Issue 1 , Pages 39-43 , April 2010

Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions

  • Carmen Flores-Staino

      Affiliations

    • Department of Clinical Pathology and Cytology, F46, Karolinska University Hospital in Huddinge, SE 14186 Stockholm, Sweden
    • Corresponding Author InformationCorresponding author.
    • ,
  • Eva Darai-Ramqvist

      Affiliations

    • Department of Clinical Pathology and Cytology, F46, Karolinska University Hospital in Huddinge, SE 14186 Stockholm, Sweden
    • ,
  • Katalin Dobra

      Affiliations

    • Department of Clinical Pathology and Cytology, F46, Karolinska University Hospital in Huddinge, SE 14186 Stockholm, Sweden
    • ,
  • Anders Hjerpe

      Affiliations

    • Department of Clinical Pathology and Cytology, F46, Karolinska University Hospital in Huddinge, SE 14186 Stockholm, Sweden
    • Department of Laboratory Medicine, Karolinska Institutet, F46, Karolinska University Hospital in Huddinge, SE 14186 Stockholm, Sweden

Received 20 October 2008 ,Revised 11 May 2009 ,Accepted 11 May 2009.

References 

  1. Brock MV, Hooker CM, Young R, Guo M, Han Y, Ames SE, et al. Can we improve the cytologic examination of pleural effusions using molecular analysis?. Ann Thorac Surg. 2005;80:1241–1247
  2. Mutsaers SE. Mesothelial cells: their structure, function and role in serosal repair. Respirology. 2002;7:171–191
  3. Foley-Comer AJ, Herrick SE, Al-Mishlab T, Prêle CM, Laurent GJ, Mutsaers SE. Evidence for incorporation of free-floating mesothelial cells as a mechanism of serosal healing. J Cell Sci. 2002;115:1383–1389
  4. Illei PB, Ladanyi M, Rusch VW, Zakowski MF. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer. 2003;99:51–56
  5. Brockstedt U, Gulyas M, Dobra K, Dejmek A, Hjerpe A. An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma. Am J Clin Pathol. 2000;114:203–209
  6. Nurminen M, Dejmek A, Mårtensson G, Thylén A, Hjerpe A. Clinical utility of liquid-chromatographic analysis of effusions for hyaluronate content. Clin Chem. 1994;40(5):777–780
  7. Onofre FB, Onofre AS, Pomjanski N, Buckstegge B, Grote HJ, Böcking A. 9p21 deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM and AgNOR analysis. Cancer (Cancer Cytopathol). 2008;114(3):204–215
  8. Shin HJ, Shin DM, Tarco E, Sneige N. Detection of numerical aberrations of chromosomes 7 and 9 in cytologic specimens of pleural malignant mesothelioma. Cancer. 2003;9:233–239
  9. Lindholm PM, Salmenkivi K, Vauhkonen H, Nicholson AG, Anttila S, Kinnula VL. Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH. Cytogenet Genome Res. 2007;119(1–2):46–52
  10. Segal A, Whitaker D, Sterrett GF, Frost FA, Robinson BWS, Olsen N, et al. Cytological diagnosis of pleural malignant mesothelioma. In: The 9th international conference of the IMIG (International Mesothelioma Interest Group). Amsterdam, The Netherlands, September 25–27. 2008;

PII: S0169-5002(09)00268-2

doi: 10.1016/j.lungcan.2009.05.004

Lung Cancer
Volume 68, Issue 1 , Pages 39-43 , April 2010

Article Tools

* Image Usage & Resolution